Tags: Drug.

Sipuleucel-T (APC8015 trade name Provenge) manufactured by Dendreon Corporation is a therapeutic cancer vaccine for prostate cancer (CaP). It must be prepared specifically for each patient. In metastatic prostate cancer it has extended survival by median 4.1 months (IMPACT Phase III trial data). The treatment costs $93000.

ATC prefix
L03
ATC suffix
AX17
CAS number
917381-47-6
FDA UNII code
8Q622VDR18

Loading...

This page contains content from the copyrighted Wikipedia article "Sipuleucel-T"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.